Literature DB >> 21907282

Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.

Robert P Carson1, Dominic L Van Nielen, Peggy A Winzenburger, Kevin C Ess.   

Abstract

Tuberous Sclerosis Complex (TSC) is a multiorgan genetic disease that prominently features brain malformations (tubers) with many patients suffering from epilepsy and autism. These malformations typically exhibit neuronal as well as glial cell abnormalities and likely underlie much of the neurological morbidity seen in TSC. Tuber pathogenesis remains poorly understood though upregulation of the mTORC1 signaling pathway in TSC has been consistently demonstrated. Here we address abnormal brain development in TSC by inactivating the mouse Tsc1 gene in embryonic neural progenitor cells. This strategy permits evaluation of the role of the Tsc1 gene in both neuronal as well as glial cell lineages. Tsc1(Emx1-Cre) conditional knockout (CKO) animals die by 25 days of life. Their brains have increased size and contain prominent large cells within the cerebral cortex that have greatly increased mTORC1 signaling and decreased mTORC2 signaling. Severe defects of cortical lamination, enlarged dysmorphic astrocytes and decreased myelination were also found. Tsc1(Emx1-Cre) CKO mice were then treated with rapamycin to see if the premature death and brain abnormalities can be rescued. Postnatal rapamycin treatment completely prevented premature death and largely reversed the glia pathology but not abnormal neuronal lamination. These findings support a model that loss of function of the TSC genes in embryonic neural progenitor cells causes cortical malformations in patients with TSC. The dramatic effect of rapamycin suggests that even with extensive multi-lineage abnormalities, a postnatal therapeutic window may exist for patients with TSC.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907282      PMCID: PMC3225598          DOI: 10.1016/j.nbd.2011.08.024

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  49 in total

1.  The utility of tuberless models of tuberous sclerosis.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2007-08       Impact factor: 5.864

2.  Cortex- and striatum- derived neural stem cells produce distinct progeny in the olfactory bulb and striatum.

Authors:  Sandrine Willaime-Morawek; Derek van der Kooy
Journal:  Eur J Neurosci       Date:  2008-05       Impact factor: 3.386

Review 3.  The diverse clinical manifestations of tuberous sclerosis complex: a review.

Authors:  Tena Rosser; Ashok Panigrahy; William McClintock
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

4.  The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.

Authors:  R F Lamb; C Roy; T J Diefenbach; H V Vinters; M W Johnson; D G Jay; A Hall
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

Review 5.  Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis.

Authors:  A C Jones; M M Shyamsundar; M W Thomas; J Maynard; S Idziaszczyk; S Tomkins; J R Sampson; J P Cheadle
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

6.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

7.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

8.  Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.

Authors:  Dan Ehninger; Sangyeul Han; Carrie Shilyansky; Yu Zhou; Weidong Li; David J Kwiatkowski; Vijaya Ramesh; Alcino J Silva
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

9.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

10.  Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis.

Authors:  K Ridler; E T Bullmore; P J De Vries; J Suckling; G J Barker; S J Meara; S C Williams; P F Bolton
Journal:  Psychol Med       Date:  2001-11       Impact factor: 7.723

View more
  84 in total

1.  Activating the translational repressor 4E-BP or reducing S6K-GSK3β activity prevents accelerated axon growth induced by hyperactive mTOR in vivo.

Authors:  Xuan Gong; Longbo Zhang; Tianxiang Huang; Tiffany V Lin; Laura Miyares; John Wen; Lawrence Hsieh; Angélique Bordey
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

Review 2.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 3.  Potential for treatment of severe autism in tuberous sclerosis complex.

Authors:  Tanjala T Gipson; Gwendolyn Gerner; Mary Ann Wilson; Mary E Blue; Michael V Johnston
Journal:  World J Clin Pediatr       Date:  2013-08-08

4.  Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTOR.

Authors:  A Oguro-Ando; C Rosensweig; E Herman; Y Nishimura; D Werling; B R Bill; J M Berg; F Gao; G Coppola; B S Abrahams; D H Geschwind
Journal:  Mol Psychiatry       Date:  2014-10-14       Impact factor: 15.992

5.  Seizure-dependent mTOR activation in 5-HT neurons promotes autism-like behaviors in mice.

Authors:  John J McMahon; Wilson Yu; Jun Yang; Haihua Feng; Meghan Helm; Elizabeth McMahon; Xinjun Zhu; Damian Shin; Yunfei Huang
Journal:  Neurobiol Dis       Date:  2014-10-12       Impact factor: 5.996

6.  Prevention of premature death and seizures in a Depdc5 mouse epilepsy model through inhibition of mTORC1.

Authors:  Lindsay K Klofas; Brittany P Short; Chengwen Zhou; Robert P Carson
Journal:  Hum Mol Genet       Date:  2020-05-28       Impact factor: 6.150

Review 7.  Genetic animal models of malformations of cortical development and epilepsy.

Authors:  Michael Wong; Steven N Roper
Journal:  J Neurosci Methods       Date:  2015-04-21       Impact factor: 2.390

8.  mTOR promotes pituitary tumor development through activation of PTTG1.

Authors:  R Chen; J Duan; L Li; Q Ma; Q Sun; J Ma; C Li; X Zhou; H Chen; Y Jing; S Zhao; X Wu; H Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

9.  Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.

Authors:  Avery J Zucco; Valentina Dal Pozzo; Alina Afinogenova; Ronald P Hart; Orrin Devinsky; Gabriella D'Arcangelo
Journal:  Mol Cell Neurosci       Date:  2018-08-23       Impact factor: 4.314

Review 10.  A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Authors:  David M Feliciano; Tiffany V Lin; Nathaniel W Hartman; Christopher M Bartley; Cathryn Kubera; Lawrence Hsieh; Carlos Lafourcade; Rachel A O'Keefe; Angelique Bordey
Journal:  Int J Dev Neurosci       Date:  2013-02-26       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.